Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease

Keyphrases

• Add-on Therapy 12%
• Adverse Effects 12%
• Adverse Events 12%
• Cochrane Central Register of Controlled Trials 12%
• Cochrane Library 12%
• Conference Proceedings 12%
• Confidence Interval 87%
• Conflicting Results 12%
• Disease Progression 12%
• Dopamine Agonist 87%
• Early Parkinson's Disease 100%
• Early Treatment 12%
• Embase 12%
• Issue 1 12%
• Levodopa 75%
• Levodopa Therapy 12%
• MEDLINE 12%
• Methodological Quality 12%
• Monoamine Oxidase B Inhibitors 100%
• Motor Fluctuations 25%
• Movement Disorders 12%
• Neurology 12%
• Non-associated 12%
• Odds Ratio 87%
• Parkinson's Disease 25%
• Random Effects Model 12%
• Randomized Controlled Trial 12%
• Selegiline 25%
• Symptomatic Effect 12%
• Unblinding 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Add on Therapy 10%
• Adverse Event 10%
• Disease Exacerbation 10%
• Dopamine Receptor Stimulating Agent 100%
• Levodopa 70%
• Monoamine Oxidase B Inhibitor 100%
• Motor Dysfunction 10%
• Parkinson's Disease 100%
• Random Effects Model 10%
• Randomized Controlled Trial 10%
• Selegiline 20%

Neuroscience

• Adverse Effect 10%
• Agonist 10%
• Dopamine Agonist 100%
• L-DOPA 70%
• Monoamine Oxidase B 100%
• Parkinson's Disease 100%
• Randomized Controlled Trial 10%
• Selegiline 20%
• Stereotypic Movement Disorder 10%
• Treatment of Parkinson's Disease 10%